The atopic dermatitis (AD) market is on track to reach $16.7 billion across mature markets by 2030, according to data and analytics company GlobalData. 19 September 2024
Danish clinical-stage techbio firm Evaxion Biotech, which is developing AI-Immunology powered vaccines, announced new clinical Phase II data for its lead compound EVX-01. 9 September 2024
Danish dermatology specialist LEO Pharma has presented a range of new population-level and physician-reported data on the prevalence, severity and treatment of moderate to severe chronic hand eczema (CHE). 5 September 2024
Biocon Biologics has signed a settlement and license agreement with Johnson & Johnson that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara (ustekinumab), in Europe, the UK, Canada, and Japan. 3 September 2024
South Korea’s Celltrion yesterday announced the European Commission (EC) approval for the use of SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases. 27 August 2024
Danish dermatology specialist LEO Pharma’s Timber Pharmaceuticals subsidiary has announced disappointing results for the randomized, double-blind 12-week period of the ASCEND trial. 23 August 2024
San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) yesterday announced the pricing of an underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on August 13, 2024. 15 August 2024
Shares of American dermatology company Verrica Pharmaceuticals had a roller-coaster start to the day after announcing what it called positive trial results. 14 August 2024
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
The US subsidiary of South Korea’s Celltrion announced its US Food and Drug Administration (FDA)-approved biosimilar adalimumab-aaty has been added to the Costco member prescription program. 14 August 2024
Crown Laboratories, a privately held skincare company, and Nashville, USA-based Revance Therapeutics have entered into an agreement whereby the companies seek to merge the two complementary organizations. 13 August 2024
BioNTech released positive top-line data from the ongoing Phase II clinical trial in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment. 30 July 2024
California’s Arcutis Biotherapeutics, a biopharma developing innovations in immuno-dermatology, has announced the US commercial launch of Zoryve (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age six years. 30 July 2024
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines for approval at its July 2024 meeting. 26 July 2024
“Circle of Goodness,” one of Russia’s largest public funds, specializing on procurements of drugs for children with rare diseases, will begin procurements of the US drug Vyjuvek (beremagen heperpavec), which is designed for patients with epidermolysis bullosa (butterfly syndrome), reports The Pharma Letter’s local correspondent. 25 July 2024
Of all the talk about the pros and cons of AbbVie’s $63 billion takeover of Allergan – which was announced on Tuesday – perhaps the most compelling came from Stat News. 26 June 2019
Almirall has exercised its option to license rights to develop and commercialize lebrikizumab for the treatment of atopic dermatitis and certain other indications in Europe from USA-based Dermira. 25 June 2019
Expectations that AbbVie would soon spend its significant cash pile have been answered by the US pharma company in a big way, with the announcement that it is to acquire Ireland-incorporated drugmaker Allergan for $63 million. 25 June 2019
Positive Phase II results on the first topical gene therapy sent a US biotech company’s share price up by 27% in Monday morning’s trading. 24 June 2019
Bristol-Myers Squibb has announced that, to help proceed its $74 billion acquisition of biotech major Celgene, it would sell one of the latter’s top-selling drugs, Otezla (apremilast). 24 June 2019
Today, at the 24th World Congress of Dermatology (WCD) taking place in Milan, Italy, US biotech firm Incyte (Nasdaq: INCY) presented 24-week data from its Phase II study evaluating ruxolitinib cream as a treatment for adult patients with vitiligo. 15 June 2019
Indian drugmaker Sun Pharmaceutical Industries’ Ilumya is impressing in a new indication beyond its current plaque psoriasis label, new data presented at EULAR has shown. 14 June 2019
US pharma major Eli Lilly presented results at EULAR on Friday from the Phase IIIb/IV SPIRIT trial comparing its drug Taltz (ixekizumab) with AbbVie’s Humira (adalimumab) in active psoriatic arthritis (PsA). 13 June 2019
Novartis has boasted that Cosentyx (secukinumab) has become the first drug to show efficacy in all key manifestations of psoriatic arthritis (PsA). 12 June 2019
US drugmaker AbbVie’s hopes that Skyrizi (risankizumab) will help to replace revenues lost when Humira (adalimumab) competition starts to bite, have been boosted further. 11 June 2019
US biotech major Celgene (Nasdaq: CELG) presented data from the first full readout of the APPRECIATE real-world evidence (RWE) study at the World Congress of Dermatology (WCD) in Milan. APPRECIATE is the largest RWE study of Otezla (apremilast), involving 480 patients across six European countries. 11 June 2019
Shares in UK-based antibiotics developer Motif Bio are now worth just a tenth of their value of four months ago after more bad news about iclaprim, the company’s lead product. 7 June 2019
Germany-headquartered clinical-stage biotech InflaRx (Nasdaq: IFRX) saw its shares crash nearly 92% to $3.06 by close of trading on Wednesday, after the company revealed that IVX-1, its potential treatment for an inflammatory skin disorder, failed to demonstrate statistical significance compared to placebo. 6 June 2019
Patients must always be the center around which the entire innovation process revolves, while seeking to satisfy unmet patient needs, writes Alfredo Barón de Juan, Executive Vice President, Global Commercial Operations at Almirall, in an Expert View piece. 5 June 2019
Privately-held Danish medical dermatology specialist LEO Pharma today announced that Gitte Aabo will step down as president and chief executive after 27 years in the company, 11 of which were as CEO. 4 June 2019
Spanish dermatology specialist Almirall and its US affiliate, formerly known as Aqua Pharmaceuticals, have agreed to pay the United States $3.5 million to resolve allegations that they used kickbacks to induce physicians to purchase their dermatology products. 30 May 2019
Shares of US biopharma company Cara Therapeutics, which were suspended ahead of the announcement, leapt as much as 21% after it released positive top-line data from the KALM-1 pivotal Phase III trial of Korsuva (CR845/difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). 29 May 2019
Russia’s first original drug for the treatment of severe psoriasis has been registered by one of the leading local drugmakers Biocad, according to the company. 22 May 2019